loader
Please Wait
Applying Filters...
menu
    • menu

    Digital Content for Tipelukast

    Client Email Product
    EUROAPI, the leading small molecules API player, provides both API sales & CDMO services.

    Virtual Booth

    Contact Supplier

    Bora Pharmaceuticals- Making success more certain.

    Virtual Booth

    Contact Supplier

    Polfa Tarchomin is a leading Polish pharmaceutical company with 200 year tradition in manufacture and sale of pharmaceutical products.

    Virtual Booth

    Contact Supplier

    Minakem offers CDMO services for API & HPAPI, generics, regulatory expertise, track record performance & FDA & GMP certifications.

    Virtual Booth

    Contact Supplier

    Axplora- The partner of choice for complex APIs.

    Virtual Booth

    Contact Supplier

    Fareva is a one-stop-shop for API/HPAPI, OSD & Sterile products, is USFDA, EMA and PMDA-inspected and has multiple NDA & ANDA filings.

    Virtual Booth

    Contact Supplier

    Menu

    Tipelukast

    DEVELOPMENTS

    DIGITAL CONTENT

    PharmaCompass
    Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    MediciNova: Two Poster Presentations On MN-001 For Cardiometabolic At EAS
    MediciNova: Two Poster Presentations On MN-001 For Cardiometabolic At EAS

    28 May 2024

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2024/05/28/2888826/7767/en/MediciNova-Announces-Two-Poster-Presentations-at-the-92nd-EAS-Congress-2024-the-Annual-Meeting-of-the-European-Atherosclerosis-Society-Regarding-the-Use-of-MN-001-Tipelukast-for-Ca.html

    GLOBENEWSWIRE
    28 May 2024
    Share Share
    X4 Pharmaceuticals Announces Proposed Public Offering
    X4 Pharmaceuticals Announces Proposed Public Offering

    06 Dec 2022

    // GLOBENEWSWIRE

    https://www.globenewswire.com//news-release/2022/12/06/2568859/0/en/X4-Pharmaceuticals-Announces-Proposed-Public-Offering.html

    GLOBENEWSWIRE
    06 Dec 2022
    Share Share
    MediciNova Receives a Notice of Allowance for a New Patent MN-001 and MN-002
    MediciNova Receives a Notice of Allowance for a New Patent MN-001 and MN-002

    13 Sep 2022

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2022/09/13/2515539/7767/en/MediciNova-Receives-a-Notice-of-Allowance-for-a-New-Patent-Covering-MN-001-and-MN-002-for-the-Treatment-of-Hypertriglyceridemia-Hypercholesterolemia-and-Hyperlipoproteinemia-in-Can.html

    GLOBENEWSWIRE
    13 Sep 2022
    Share Share
    MediciNova's MN-001 Abstract Improves Serum Lipid Panel in T2D and NAFLD
    MediciNova's MN-001 Abstract Improves Serum Lipid Panel in T2D and NAFLD

    09 Aug 2022

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2022/08/09/2495425/7767/en/MediciNova-Announces-MN-001-tipelukast-Abstract-regarding-Improvement-of-Serum-Lipid-Panel-in-Type-2-Diabetes-and-NAFLD-Patients-Accepted-for-Presentation-at-the-IDF-2022-Congress-.html

    GLOBENEWSWIRE
    09 Aug 2022
    Share Share
    MediciNova Announces Initiation of a PII Trial of MN-001 in NAFLD
    MediciNova Announces Initiation of a PII Trial of MN-001 in NAFLD

    26 Jul 2022

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2022/07/26/2485685/7767/en/MediciNova-Announces-Initiation-of-a-Phase-2-Trial-of-MN-001-tipelukast-in-NAFLD-with-Type-2-Diabetes-Mellitus-and-Hypertriglyceridemia.html

    GLOBENEWSWIRE
    26 Jul 2022
    Share Share
    MediciNova Announces MN-001 Research Collaboration with The Juntendo University
    MediciNova Announces MN-001 Research Collaboration with The Juntendo University

    22 Jun 2022

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2022/06/22/2467556/7767/en/MediciNova-Announces-MN-001-tipelukast-Research-Collaboration-with-The-Juntendo-University-School-of-Medicine-in-Tokyo-Japan.html

    GLOBENEWSWIRE
    22 Jun 2022
    Share Share